Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PPID | Q08752 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12290669 | 0.80 | NR3C2 (0.42) | NLRP3ALDH1A1HTTNR3C2 | |
| SCHEMBL5972758 | 0.76 | TSHR (0.48) | NLRP3ALDH1A1TSHRHTTMEN1 | |
| SCHEMBL2320013 | 0.75 | ALDH1A1 (0.47) | NLRP3ALDH1A1TSHRHTTMEN1 | |
| SCHEMBL12499810 | 0.75 | ALDH1A1 (0.47) | NLRP3ALDH1A1TSHRHTTMEN1 | |
| SCHEMBL10249906 | 0.75 | TSHR (0.47) | NLRP3ALDH1A1TSHRMEN1NPC1 | |
| SCHEMBL9316342 | 0.75 | ALDH1A1 (0.50) | ALDH1A1TSHRGAAMGAMSI | |
| SCHEMBL7824806 | 0.75 | NLRP3 (0.48) | NLRP3ALDH1A1MAPK1PPID | |
| SCHEMBL6841260 | 0.74 | FFAR1 (0.49) | — | |
| SCHEMBL12329342 | 0.74 | NR3C2 (0.42) | ALDH1A1TSHRHTTNR3C2MEN1 | |
| SCHEMBL363983 | 0.74 | TSHR (0.48) | NLRP3ALDH1A1TSHRGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358716-B1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | MERCK SHARP & DOHME (US) | 2016-01-06 | — | — | EP | disclosed |
| US-8815875-B2 | Inhibitors of fatty acid binding protein (FABP) | MERCK SHARP & DOHME CORP. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815875-B2 | Inhibitors of fatty acid binding protein (FABP) | MERCK SHARP & DOHME CORP. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110237575-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | MERCK SHARP & DOHME LLC | 2011-09-29 | — | — | US | disclosed |
| US-20110237575-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | MERCK SHARP & DOHME LLC | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237575-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | FABP4, FABP1, FABP3 | NLRP3 2129/4885ALDH1A1 781/4885TSHR 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.